Mazieres J, Iadeluca L, Shaw AT, Solomon BJ, et al. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer 2022;174:146-156.
PMID: 36410210